RxDoctor Payments DataLook up a doctor →

Michael Huffman, MD

Family Medicine · Lincoln, NENPI 1386607182

Payments from drug & device makers

$10,674in general payments, 2019–2025

Across 777 payments — averaging $13.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Amgen$885
  • Boehringer Ingelheim$689
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,665100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,674 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$206,047
Medicare patients
498
Services billed
3,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$88,623
JardianceEmpagliflozin49$74,156
RybelsusSemaglutide29$37,977
MounjaroTirzepatide28$32,153
EliquisApixaban18$23,347
EntrestoSacubitril/Valsartan13$9,602
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,418
MyrbetriqMirabegron15$7,341
Tresiba Flextouch U-100Insulin Degludec11$5,255
Incruse ElliptaUmeclidinium Bromide12$4,319
SymbicortBudesonide/Formoterol Fumarate17$4,095
Omeprazole215$3,047
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,437
SynthroidLevothyroxine Sodium28$2,265
Levothyroxine Sodium245$2,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,540$126,60090 claims
Boehringer IngelheimJardiance$689$74,15649 claims
Lilly USA, LLCMounjaro$1,217$32,15328 claims
PfizerEliquis$638$23,34718 claims
GSKAnoro Ellipta, Incruse Ellipta$14$12,73830 claims
NovartisEntresto$232$9,60213 claims
Astellas Pharma US IncMyrbetriq$292$7,34115 claims
AstraZenecaSymbicort$1,103$4,09517 claims
AbbVieSynthroid$1,611$2,26528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →